CTOs on the Move

C2i Genomics

www.c2i-genomics.com

 
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

C2i Genomics raised $12M on 06/09/2020
C2i Genomics raised $100M on 04/15/2021

Similar Companies

Arno Therapeutics, Inc.

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.

National Institutes of Health

The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...

Bruker

Bruker is a Goleta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accurate Automation

Accurate Automation Corp. is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Catamaran Bio

Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWINDTM Platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures and Astellas Venture Management.